Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
Mariano ProvencioErnest NadalJosé L González-LarribaAlex Martínez-MartíReyes BernabéJoaquim Bosch-BarreraJoaquín Casal-RubioVirginia CalvoAmelia InsaSantiago PonceNoemí ReguartJavier de CastroJoaquín MosqueraManuel CoboAndrés AguilarGuillermo López VivancoCarlos CampsRafael López-CastroTeresa MoránIsidoro BarnetoDelvys Rodríguez-AbreuRoberto Serna-BlascoRaquel BenítezCarlos Aguado de la RosaRamón PalmeroFlorentino Hernando-TranchoJavier Martín-LópezAlberto Cruz-BermúdezBartomeu MassutiAtocha RomeroPublished in: The New England journal of medicine (2023)
In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone. (Funded by Bristol Myers Squibb and others; NADIM II ClinicalTrials.gov number, NCT03838159; EudraCT number, 2018-004515-45.).